雷尼替丁与复方丹参联合治疗急性胰腺炎35例疗效分析

目的：观察雷尼替丁与复方丹参联合治疗急性胰腺炎的疗效。方法：对确诊急性胰腺炎65例随机分成治疗组35例,对照组30例,分别用常规治疗,常规治疗加雷尼替丁与复方丹参静滴,连用4－7天,评价其疗效。结果：治疗组与对照组显效率分别为85.71%、43.3%,两组差异显著,P＜0.05。结论：两药联合应用不仅可减轻本病的炎症病变,且可改善心肌细胞营养状况。     

奥美拉唑三联疗法治疗小儿消化性溃疡的临床研究

目的探讨奥美拉唑三联疗法治疗小儿消化性溃疡的临床疗效。方法选择2020年1月—2021年1月在新郑市中医院就诊治疗的90例消化性溃疡患儿,按照入院先后顺序将所有患儿分为对照组和治疗组,每组各45例。对照组采用雷尼替丁三联疗法进行治疗:口服盐酸雷尼替丁胶囊,3～5 mg/(kg·d),2次/d;口服克拉霉素缓释片,15～20 mg/(kg·d),2次/d;口服阿莫西林胶囊,30～50mg/(kg·d),2次/d。治疗组采用奥美拉唑三联疗法进行治疗:口服奥美拉唑肠溶胶囊,0.6～0.8mg/(kg·d),1次/d;克拉霉素缓释片、阿莫西林胶囊用法用量均与对照组相同。两组患儿治疗6周。观察两组患儿的临床疗效,比较两组患儿治疗前后的炎性因子水平、胃肠道激素水平。结果治疗后,治疗组患儿的总有效率(93.33%)高于对照组(77.78%),组间比较有显著差异(P<0.05)。治疗后,两组患儿血清白细胞介素-25(IL-25)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平均明显降低,有统计学差异(P<0.05);治疗后治疗组患儿血清IL-25、CRP、TNF-α水平均低于对照...     

Intolerance to Cereals Is Not Specific for Coeliac Disease

Background: While dyspeptic patients in primary care often receive empirical treatment with antisecretory drugs, a substantial number suffer from motility disturbances which may be associated with their complaints. We aimed to compare the effectiveness of treatment with antisecretory treatment with a prokinetic agent in uninvestigated dyspepsia. Methods: 563 patients presenting dyspeptic complaints to the general practitioner with a low likelihood of organic (ulcer, reflux or malignant) disease, i.e. absence of alarm symptoms or a history of peptic ulcer disease or gastro-oesophageal reflux disease were included. They entered a randomized, double-blind trial of 4 weeks of ranitidine 150 mg bid compared with 4 weeks of cisapride 10 mg bid, with 3 months follow-up. Treatment failure was defined as no response to treatment or a relapse of symptoms within the follow-up period. Also studied were the effect on dyspepsia severity, response to treatment after 4 weeks, and time to relapse. Results: For all randomized patients, the incidence of overall treatment success after 3 months follow-up with antisecretory treatment was 107/271 (39.5%) and with a prokinetic agent 122/282 (43.3%); the risk difference was 3.8% (95% CI-4.4% to 12.0%); the difference in symptom severity score after 4 weeks of treatment was 0.3; 95% CI-0.4% to 1.0%. For patients responding to 4 weeks of treatment, relapsefree time was 86 days in the prokinetic group and 79 days in the acid suppression group (P = 0.005). Conclusions: Antisecretory and prokinetic therapies are equally effective in primary care patients with uninvestigated dyspeptic complaints, though relapse rates are lower in patients treated with prokinetic treatment.     

Effect of long-term administration of ranitidine,a histamine H2 receptor antagonist,on bone metabolism in young growing rats

Background

Histamine regulates function of osteoclasts and osteoblasts, however data regarding the influence of histamine H2 receptors antagonists on bone tissue are ambiguous. Factors that influence growing skeleton may have an important impact on the peak bone mass and future risk of fractures. The aim of our study was the assessment of influence of ranitidine, on growing bones.

含雷贝拉唑与枸橼酸铋雷尼替丁的两种三联疗法治疗消化性溃疡的疗效比较

目的:比较含雷贝拉唑(RAZ)与枸橼酸铋雷尼替丁(RBC)的两种三联疗法治疗消化性溃疡的临床疗效。方法:将确诊为消化性溃疡的患者148例按随机数字表法均分为RAZ组和RBC组,分别给予RAZ/RBC+克拉霉素+甲硝唑的三联疗法治疗1周,之后两组患者均单服RAZ或RBC治疗3周,疗程共4周。治疗结束后比较两组患者的疗效、溃疡愈合率和幽门螺杆菌(Hp)根除情况,并观察治疗中的不良反应。结果:治疗结束后,RAZ组与RBC组患者的临床总有效率分别为88.7%、83.3%,Hp根除率分别为87.3%、93.1%,溃疡愈合率分别为85.9%、87.5%,两组比较差异均无统计学意义(P>0.05)。两组患者的不良反应均较轻,不影响治疗,可自行好转。结论:含RAZ与RBC的两种三联疗法治疗消化性溃疡的疗效相当,且安全性均较好。     

Upper gastro-intestinal tract bleeding in cirrhotic children candidates for liver transplantation

Signs of portal hypertension, history of upper gastro-intestinal tract bleeding episodes and outcome of the latter were recorded in 76 cirrhotic children evaluated for liver transplantation. Fifty-three (70%) had varices and 22 (29%) had experienced upper gastro-intestinal tract bleeding. Of these 22, 19 bled from varices and 3 from ulcers. Non bleeding ulcers were also found in five patients bleeding from varices. Iterative sclerotherapy controlled acute variceal bleeding in all but one patient in whom emergency transplantation was performed. Six of the eight patients with ulcers were successfully treated by the H2 histamine receptor antagonist ranitidine. We conclude that iterative sclerotherapy is efficient to control acute variceal bleeding and prevents recurrent bleeding in children with end-stage liver diseases awaiting liver replacement. Bleeding asymptomatic ulcers are frequent and respond to H2 histamine receptor antagonists.     

Ranitidine-induced bradycardia in a neonate — a first report

Bradycardia, an extremely rare side-effect of ranitidine therapy is described in a 4-day-old full-term male neonate, who was admitted because of massive gastro-intestinal bleeding. Two hours after the intravenous injection of 1 mg/kg body weight per day, ECG showed sinus bradycardia of 60 beats/min with normal axis and QRS complex.The bradycardia gradually resolved in the next 24 h.     

奥美拉唑治疗消化性溃疡的疗效及不良反应观察

目的　 探讨奥美拉唑治疗消化性溃疡的效果及不良反应的发生情况 ,以便指导临床用药。方法　 对比分析奥美拉唑与雷尼替丁治疗消化性溃疡的疗效及不良反应。结果　 奥美拉唑组的治疗效果明显优于雷尼替丁组 (P <0 .0 1) ;而不良反应明显低于雷尼替丁组 (P <0 .0 1)。结论　奥美拉唑是目前临床治疗消化性溃疡最安全有效的药物 ,值得推广应用     

A randomized placebo controlled trial of ranitidine versus sucralfate in patients with spontaneous intracerebral hemorrhage for prevention of gastric hemorrhage

AIM: Due of paucity of studies on stress ulcer prophylaxis in intracerebral hemorrhage (ICH), we have evaluated the usefulness of ranitidine and sucralfate in preventing gastric hemorrhage (GH) in patients with ICH. SUBJECTS AND METHODS: In a hospital-based randomized placebo-controlled study, patients with CT-proven ICH within 7 days of ictus were randomized into ranitidine 50 mg i.v. eight hourly, sucralfate 1 g six hourly and placebo groups. Patients were conservatively managed. Primary endpoint was occurrence of GH within 15 days of ictus and secondary endpoint 1-month mortality. RESULTS: The mean age of the patients was 57.2 (range 25-90) years and 40 were females. There were 45 patients in ranitidine, 49 in sucralfate and 47 in placebo group. Demographic, clinical and radiological features were not significantly different in 3 groups. GH occurred in 11 (23.4%) patients in placebo, 5 (11.1%) in ranitidine and 7 (14.3%) in sucralfate group, which was not significant. Only one female had GH. There were 13 (27.7%) deaths in placebo, 5 (11.1%) in ranitidine and 12 (24.5%) in sucralfate group. Pneumonia occurred in placebo group in 5 (10.6%), ranitidine in 2 (4.4%) and sucralfate in 5 (10.2%) patients, which was not significantly different. CONCLUSION: Ranitidine and sucralfate do not seem to significantly prevent GH or reduce 1-month mortality.